Stockreport

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Adagene Inc. - ADS, each representing 1.25 ordinary shares  (ADAG) 
PDF Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 202 [Read more]